On Friday, ProQR Therapeutics N.V (NASDAQ: PRQR) was -3.29% drop from the session before settling in for the closing price of $3.95. A 52-week range for PRQR has been $1.18 – $4.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 44.49%. When this article was written, the company’s average yearly earnings per share was at 4.24%. With a float of $73.25 million, this company’s outstanding shares have now reached $78.46 million.
In terms of profitability, gross margin is 92.11%, operating margin of -166.82%, and the pretax margin is -134.62%.
ProQR Therapeutics N.V (PRQR) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward ProQR Therapeutics N.V stocks. The insider ownership of ProQR Therapeutics N.V is 29.02%, while institutional ownership is 17.68%.
ProQR Therapeutics N.V (PRQR) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.08 earnings per share (EPS) during the time that was better than consensus figure (set at -0.12) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.24% per share during the next fiscal year.
ProQR Therapeutics N.V (NASDAQ: PRQR) Trading Performance Indicators
You can see what ProQR Therapeutics N.V (PRQR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.32, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.39 in one year’s time.
Technical Analysis of ProQR Therapeutics N.V (PRQR)
Looking closely at ProQR Therapeutics N.V (NASDAQ: PRQR), its last 5-days average volume was 0.82 million, which is a jump from its year-to-date volume of 0.53 million. As of the previous 9 days, the stock’s Stochastic %D was 59.42%. Additionally, its Average True Range was 0.32.
During the past 100 days, ProQR Therapeutics N.V’s (PRQR) raw stochastic average was set at 73.42%, which indicates a significant increase from 53.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.45% in the past 14 days, which was lower than the 139.17% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.72, while its 200-day Moving Average is $2.17. However, in the short run, ProQR Therapeutics N.V’s stock first resistance to watch stands at $3.98. Second resistance stands at $4.15. The third major resistance level sits at $4.29. If the price goes on to break the first support level at $3.67, it is likely to go to the next support level at $3.53. Should the price break the second support level, the third support level stands at $3.36.
ProQR Therapeutics N.V (NASDAQ: PRQR) Key Stats
There are 81,680K outstanding shares of the company, which has a market capitalization of 381.27 million. As of now, sales total 7,050 K while income totals -30,430 K. Its latest quarter income was 4,230 K while its last quarter net income were -8,920 K.
